Skip to content

Study · Not a test of the peptide alone · 2003

1 result

Comparative evaluation of four trityl-type amidomethyl polystyrene resins in Fmoc solid phase peptide synthesis.

Zikos C, Livaniou E, Leondiadis L, Ferderigos N, Ithakissios DS, Evangelatos GP

Journal of peptide science : an official publication of the European Peptide Society1 Jul 2003Cited by 13 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

  1. 01LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cell-free)Other

    In Fmoc solid phase synthesis on four trityl-type amidomethyl polystyrene resins, pure thymosin beta‑4 was obtained with a yield of approximately 30% from each resin.

    In plain wordsIn lab chemistry, four types of resin each gave about 30% yield of pure thymosin beta‑4.

    Outcome
    Not applicableYield of synthetic thymosin beta-4 from four trityl-type resins
    Study

    n: not reported in source

    Fmoc solid phase peptide synthesis on trityl-type amidomethyl polystyrene resins
    Outcome group
    Synthesis and manufacturing · Pharmacology

    Measurements

    Final yield
    ≈ 30%
    each resin

    Source sentences

    Summary
    Independent of their differences in acid sensitivity, the resins seemed to function equally well under the conditions used, since pure thymosin beta-4 was obtained with a final yield of approximately 30% from each resin.
    1 context sentence
    Summary · context
    The above resins were applied, in parallel with Wang benzyl-type resin, well known for its stability in mild acidic conditions, to the Fmoc solid phase synthesis of the 43-amino acid residue long bioactive peptide thymosin beta-4.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.